Stockscreener 앱 받기
13.41
0.53%
0.0912
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
What analysts say about Sarepta Therapeutics Inc. stockOutperformance with explosive growth - jammulinksnews.com
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - Zacks Investment Research
Sarepta Makes A 'Painful' Decision, And Shares Tumble - Investor's Business Daily
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review - Benzinga
Sarepta to Pause Shipments of the Gene Therapy Elevidys - Managed Healthcare Executive
Sarepta Therapeutics stock sinks further Tuesday after halting shipment of bestselling drug Elevidys - Yahoo Finance
Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys - BioSpace
Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths - The New York Times
Sarepta Therapeutics’ stock slips further as company bows to FDA pressure to halt shipments - MarketWatch
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT - GlobeNewswire
Sarepta Therapeutics Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com
Sarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at JPMorgan Chase & Co. - Defense World
Sarepta to pause Elevidys gene therapy shipments in U.S. (SRPT:NASDAQ) - Seeking Alpha
Is Sarepta Therapeutics Inc. a good long term investmentRecord-breaking gains - jammulinksnews.com
Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) – Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire
Sarepta slides further after it reverses course and says it will stop shipments of gene therapy - Sherwood News
Sarepta stops Elevidys shipments after standoff with FDA - BioPharma Dive
Sarepta to pause gene therapy Elevidys shipments in U.S. - CNBC
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - Bloomberg.com
Sarepta halts US shipments of Duchenne therapy, bowing to FDA - Endpoints News
In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy - statnews.com
Sarepta to pause gene therapy Elevidys shipments in US - TradingView
Sarepta bows to FDA pressure, pulls Duchenne therapy from market - NBC Boston
Sarepta bows to FDA pressure, pulls Duchenne drug from market - The Business Journals
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. - Sarepta Therapeutics
About Face: Sarepta to Pause Elevidys Shipments Temporarily - Genetic Engineering and Biotechnology News
Sarepta’s Elevidys Halted at Children’s Hospital Los Angeles - Bloomberg.com
Sarepta under pressure: FDA requests halt of Elevidys shipments - Yahoo Finance
Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says - Bloomberg.com
Monday movers: Block, Sarepta, Etsy, Verizon and more - MarketWatch
Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA - Investor's Business Daily
Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy - The Columbus Dispatch
Sarepta Faces Regulatory Showdown As Analysts Cut Price TargetsSarepta Therapeutics (NASDAQ:SRPT) - Benzinga
The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear - statnews.com
Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha
Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths - MedPage Today
5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis - BioPharma Dive
Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest
Sarepta refuses to pull gene therapy despite FDA order - Yahoo Finance
Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma
Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse. - Barron's
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView
Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes
Cambridge-based gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - WBUR
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar
Sarepta Faces FDA Hold on Gene Therapy Trials - TipRanks
FDA places clinical hold on Sarepta’s gene therapy trials for muscular dystrophy - Investing.com
Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments - BioSpace
Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Yahoo Finance
Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com Nigeria
SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Sarepta stock extends decline as company declines FDA call to withdraw drug - MarketWatch
0.04%
0.04%
자본화:
|
볼륨(24시간):